





Global Epidemiological update

More than 3 million deaths and 144 million cases have been recorded since the start of the pandemic. WHO situation reports mentions that it took 9 months to reach the first million deaths, 4 months to reach 2 million and just 3 months to reach the 3 million deaths, and pace of death is accelerating across the globe. All regions except the European region reported an increase in cases in the past week with maximum cases reported from South East Asia driven largely by India.

as on 23 April 2021

NO OF DOSES GIVEN Covid-19 Vaccine


World	993 million
India	136 million
Nagaland	1,79,349

India is now the second most affected country by Covid-19

19,71,778 cases were reported in the past week with 12,612 deaths. This is the **highest cases and deaths reported in a single week since the start of the Pandemic.** Maharashtra, Uttar Pradesh, Karnataka, Kerala, Chhattisgarh, Rajasthan, Gujarat, Delhi, Tamil Nadu and Madhya Pradesh are the most affected states.

Globally, India has the second highest number of reported cases after USA.

India: Weekly New Cases



Global | National | State

As on 23 April 2	2021		
Covid 19 Ca	cases	Deaths	Death Rate
World	14,43,58,956	30,66,113	2.12%
India	1,62,63,695	1,86,920	1.15%
Nagaland	12,889	84	0.65%

In the past week:

World: 56,70,573 cases and 87,178 deaths.

India: 19,71,778 cases and 12,612 deaths.

Nagaland: 385 cases and 1 deaths.

	Indi	a %	Naga	land %	India	%	Naga	land %
Age Group	2020	2021	2020	2021	2020	2021	2020	2021
<10	2.9	4.03	3	2	0.2	0.3	0	0
10-20	8.5	8.0	8	12	0.5	0.3	0	0
20-30	19.3	20.4	30	40	2.0	1.7	8	0
30-40	21.1	21.0	34	21	5.2	5.3	21	8
40-50	17.5	17.1	15	11	11.9	10.8	18	15
50-60	15.0	14.8	7	9	23.2	21.2	13	38
60-70	9.9	9.0	2	4	28.7	28.2	13	8
70-80	41.	4.1	0.7	2	19.9	22.1	18	23
>80	1.2	1.3	0.2	1	7.8	9.8	8	8

As the state is early into the second wave, data may not be representative of the actual picture in the coming months.

Current active cases in No	rth Eastern States
Assam	11918
Meghalaya	1133
Lakshadweep	803
Sikkim	640
Mizoram	608
Tripura	563
Manipur	513
Nagaland	456
Arunachal Pradesh	380

AREAS OF CONCERN

- The positivity rate has increased from 2.3% in March 2021 to 8.9% in April 2021 which is close to Positivity Rate in August 2020.
- The high Weekly Sample Positivity Rate in Dimapur (24) and Kohima (11) is alarming as high positivity rate signifies undetected cases in the population.
- Social gatherings and events remain high risk for super spreader events in the state when positivity rate is high.
- High positivity rate among returnees and travellers and non-adherence to quarantine measures. The numerous points of entry to the state and the porous border make it extremely difficult to monitor everyone at points of entry. The community and ward/village councils should ensure quarantine of 10 days as in SOP if there is no negative RT PCR report. Travellers should be equally responsible.

COVID-19 VACCINATION IN NAGALAND Source: UIP, DHFW


1,79,349 doses have been administered across the state till date.

District	Total doses administered
Dimapur	51487
Kohima	27746
Mokokchung	20661
Mon	17711
Phek	13371
Wokha	11502
Tuensang	10847
Zunheboto	9725
Peren	6055
Longleng	5762
Kiphire	4482
State	1,79,349


Category	Total doses administered
45 years and above 1st dose	82,028
45 years and above 2nd dose	4,359
Healthcare workers 1st Dose	14,053
Healthcare workers 2nd Dose	9,425
Frontline workers 1st Dose	46,634
Frontline workers 2nd Dose	22,850
State	1,79,349

98% of doses have been administered in Government facilities.

TOTAL BENEFICIARIES





MONTHLY TESTING & POSITIVITY RATE



CONFIRMED CASES (weekly data)

385 confirmed cases this week





CONFIRMED CASES THIS WEEK

Age Group	Cases	%
Traced Contacts/Self-test	187	49 %
Travelers/Returnees	179	46 %
Armed forces/ Security	18	5 %
Frontline workers	1	0 %
TOTAL	385	100%

1,42,528 samples have been tested till date

2,700 samples were tested in the past week with a positivity rate of 14%


Test Type	No of tests	%
RT PCR	1039	38
TRUENAT	228	8
RAT	1434	53
TOTAL	2700	100%

COVID DEATHS IN THE STATE

Characteristics	Number	%
■ CFR/Death Rate ≤ 44 years	25/10554	0.23 %
■ CFR/Death Rate ≥ 44 years	60/2335	2.6 %
Median age of deaths	55 yrs (range 24-90 yrs)	
Age group of deaths		
24 - 44 yrs	25/85	28 %
45 - 90 yrs	60/85	71 %
Deaths with comorbidity	74/85	87 %
Deaths with pregnancy	1/23	4 %
■ Place of death		
Hospital	78/85	92 %
Home	4/85	5 %
On the way to hospital	3/85	4 %

The CFR (Case Fatality Rate) among 45 years and above is high at 2.6% which is worrisome, and the median age of Covid deaths is 55 years (range: 24-90 years). This necessitates the need for urgent Vaccination before the second wave peaks.

CLINICAL SYMPTOMS REPORTED AMONG CONFIRMED CASES IN THE STATE




ANYONE WITH ANY OF THESE REPORTED SYMPTOMS SHOULD ISOLATE and get tested.

This becomes vital in high-risk settings like offices, colleges or schools to avoid a super spreader event

DISTRICT DISTRIBUTION OF ACTIVE CASES AND SAMPLING

District	Active Cases	Deaths	Weekly Samples Tested	Weekly Positivity Rate	
Dimapur	314	54	1201	24 %	
Kohima	121	21	729	11 %	
Mokokchung	11	4	214	2 %	
Longleng	4	0	77	1 %	
Phek	3	0	142	2 %	
Peren	1	0	44	2 %	
Tuensang	1	2	91	2 %	
Wokha	1	1	33	0 %	
Kiphire	0	1	46	0 %	
Mon	0	2	102	0 %	
Zunheboto	0	0	21	0 %	
STATE	456	85	2700	14 %	



*For data reporting, Noklak is covered under Tuensang district as there is no separate surveillance unit yet for the district.

LET'S STOP COVID-19!







WEAR MASK



WASH HANDS



WATCH DISTANCE

from 1st March 2021

COVID-19 VACCINATION


for all citizens 45 years and above









VACCINATION AT GOVERNMENT FACILITIES IS FREE!





www.nsdma.nagaland.gov.in

@MyGovNagaland



(Coronaga



(DR. KEVICHÜSA MEDIKHRÜ)

Principal Director

Department of Health and Family Welfare

Kohima: Nagaland

Bibliography:

DoHFW, Nagaland; COVID-19 War Room, Nagaland; MoHFW; WHO; WCO Nagaland; NCDC, New Delhi; CDC, Atlanta; Bloomberg; NEJM; BMJ